ClinicalTrials.gg
CompletedNCT07023731Updated Nov 17, 2026

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

A Phase 1/2 interventional study of ARV-806 in KRAS G12D Mutation and Advanced Solid Cancer, sponsored by Arvinas Inc.. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Primary conditionnone(registry's first term: Pancreatic Neoplasms)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Pancreatic Neoplasms, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by Arvinas Inc. · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 17, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
76
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation. This is an open-label study which means that participants and study staff will know that all participants will receive ARV-806.

Researchers think that ARV-806 can work by breaking down a specific protein with a mutation that is present in some tumors, which might help prevent or slow tumors from growing. This will be the first time ARV-806 will be used in people. The investigational drug will be given through a vein. This is called intravenous (IV) infusion.

This study will include 2 parts:

In Part A (Phase 1), different small groups of participants will receive lower to higher doses of ARV-806. Adults with advanced cancers having a specific KRAS mutation will be included.

In Part B (Phase 2), participants will be assigned to receive one of up to 2 dose levels decided by the information from Part A. Part B will include participants with advanced pancreatic ductal cancer having a specific KRAS mutation.

02

Conditions studied

  • KRAS G12D Mutation
  • Advanced Solid Cancer

Keywords

  • KRAS G12D Mutation
  • Advanced Solid Tumors
  • KRAS G12D Mutated Advanced Solid Tumors
  • KRAS G12D Mutated Pancreatic Ductal Adenocarcinoma
  • Pancreatic Cancer
  • PDAC
  • Non-Small Cell Lung Cancer
  • NSCLC
  • Colorectal Cancer
  • Colon Cancer
  • CRC
  • Appendiceal Carcinoma
  • Cholangiocarcinoma
  • Endometrial Cancer
  • Esophageal Adenocarcinoma
  • Gallbladder Cancer
  • Gastric Cancer
  • Melanoma
  • Ovarian Cancer
  • Small Bowel Adenocarcinoma
  • Thyroid Cancer
  • advanced cancer
  • KRAS
  • G12D mutation
  • Pancreas cancer
03

In context

Lead sponsor

Arvinas Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A:

  • Histological or cytological diagnosis of unresectable or solid tumor , AND
  • Must have evidence of KRAS G12D mutation in tumor tissue or blood (circulating tumor deoxyribonucleic acid [ctDNA]), AND
  • Must have received prior standard-of-care (SOC) therapy appropriate for their type and stage of disease and have no other available treatment options with curative intent, or, in the opinion of the investigator, would be unlikely to tolerate or derive benefit from appropriate SOC therapy, AND
  • Must have at least 1

Part B:

  • Histological or cytological diagnosis of unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC) with KRAS G12D mutation status confirmed by local testing of tumor tissue using a validated molecular or next-generation sequencing (NGS) testing, AND
  • Must be willing to provide or willing to undergo pretreatment biopsy, AND
  • Must have received at least one prior standard of care systemic therapy for PDAC (systemic therapy received in the or adjuvant setting is allowed), AND
  • Participants must have at least 1 measurable lesion

Part A / Part B:

  • performance status of 0 or 1,
  • Participants with adequate organ function,
  • Participants must accept and follow pregnancy prevention guidance.

Exclusion criteria

Exclusion Criteria:

Part A / Part B:

  • Active
  • Carcinomatous meningitis
  • Uncontrolled hypertension despite optimal medical therapy
  • Prior treatment with a KRAS G12D or a KRAS G12C targeting therapy (pan-KRAS inhibitor/degrader included)
  • Participants with an inability to comply with listed prohibited treatments
  • Systemic anticancer therapy within 2 weeks or 5 half-lives (whichever is shorter) or radiation therapy (excluding palliative radiation) within 2 weeks prior to the study intervention treatment. If the last immediate anticancer treatment contained an antibody-based agent(s), then an interval of 28 days or 5 half-lives (whichever is shorter) of the agent(s) is required prior to receiving the study intervention treatment.
  • Standard 12-lead that demonstrates abnormalities that may affect participant safety or interpretation of study results
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Phase 1/Part A Monotherapy (Dose Escalation)

    Participants will receive ARV-806 at the assigned doses and regimen (weekly or every 2 weeks).

    Drug: ARV-806

  • Experimental
    Phase 2/Part B Monotherapy (Dose Expansion)

    Participants will receive ARV-806 at one of up to 2 dose levels/regimens selected from Part A)

    Drug: ARV-806

Interventions

  • DrugARV-806

    Intravenous infusion at assigned dose and dosing schedule

06

What researchers measure

Primary outcomes

  1. Part A (Phase 1): Number of dose-limiting toxicities (DLTs) of ARV-806

    Number of participants within a dose escalation cohort with adverse events (AEs) meeting protocol defined dose limiting toxicities during cycle 1 (28 days).

    Time frame: 28 days from first ARV-806 administration

  2. Part A (Phase 1): Number of participants with AEs

    AEs as characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\]), timing, seriousness, and relationship to study intervention as a measure of safety and tolerability

    Time frame: From the study baseline to at least 28 days after last dose of ARV-806

  3. Part B (Phase 2): Overall Response Rate (ORR)

    ORR is a parameter measuring the anti-tumor activity of ARV-806. ORR is the percentage of participants for whom the study treatment resulted in a complete response or partial response of the disease under study. It is measured using CT/MRI and RECIST 1.1 criteria per investigator assessment.

    Time frame: Approximately 2 years

Secondary outcomes

  1. Pharmacokinetics (PK) of ARV-806 (Part A): Area under the plasma or blood concentration-time profile during a dosing interval (AUCtau)

    Time frame: At predefined intervals throughout the treatment period, up to approximately 6 months after first dose of ARV-806

  2. PK of ARV-806 (Part A): Area under the plasma or blood concentration time profile from time zero to the time of the last quantifiable concentration (Clast) (AUClast)

    Time frame: At predefined intervals throughout the treatment period, up to approximately 6 months after first dose of ARV-806

  3. PK of ARV-806 (Part A): Maximum plasma or blood concentration (Cmax)

    Time frame: At predefined intervals throughout the treatment period, up to approximately 6 months after first dose of ARV-806

  4. PK of ARV-806 (Part A): Minimum observed concentration (Cmin)

    Time frame: Timeframe: At predefined intervals throughout the treatment period, up to approximately 6 months after first dose of ARV-806

  5. PK of ARV-806 (Part A): Plasma or blood clearance (CL)

    Time frame: At predefined intervals throughout the treatment period, up to approximately 6 months after first dose of ARV-806

  6. PK of ARV-806 (Part A): Time for Cmax (Tmax)

    Time frame: At predefined intervals throughout the treatment period, up to approximately 6 months after first dose of ARV-806

  7. PK of ARV-806 (Part A): Volume of distribution (Vd)

    Time frame: At predefined intervals throughout the treatment period, up to approximately 6 months after first dose of ARV-806

  8. Part A: Overall Response Rate (ORR)

    Time frame: Approximately 2 years

  9. Part A: Time to Response (TTR)

    Time frame: Approximately 2 years

  10. Part A: Duration of Response (DOR)

    Time frame: Approximately 2 years

  11. Part A: Disease Control Rate (DCR)

    Time frame: Approximately 2 years

  12. Part B: Number of participants with AEs

    Time frame: From the study baseline to at least 28 days after last dose of ARV-806

  13. Part B: ARV-806 whole blood pre and post dose concentration

    Time frame: At predefined intervals throughout the treatment period, up to approximately 6 months after first dose of ARV-806

  14. Part B: Time to Response (TTR)

    Time frame: Approximately 2 years

  15. Part B: Duration of Response (DOR)

    Time frame: Approximately 2 years

  16. Part B: Disease Control Rate (DCR)

    Time frame: Approximately 2 years

07

Study locations

14 sites
  • Clinical Trial Site
    Phoenix, Arizona 85004, United States
  • Clinical Trial Site
    Phoenix, Arizona 85054, United States
  • Clinical Trial Site
    New Haven, Connecticut 06510, United States
  • Clinical Trial Site
    Tampa, Florida 33612, United States
  • Clinical Trial Site
    Indianapolis, Indiana 46250, United States
  • Clinical Trial Site
    Grand Rapids, Michigan 49546, United States
  • Clinical Trial Site
    New York, New York 10032, United States
  • Clinical Trial Site
    New York, New York 10065, United States
  • Clinical Trial Site
    Huntersville, North Carolina 28078, United States
  • Clinical Trial Site
    Cleveland, Ohio 44106, United States
  • Clinical Trial Site
    Houston, Texas 77030-7009, United States
  • Clinical Trial Site
    San Antonio, Texas 78229, United States
  • Clinical Trial Site
    Salt Lake City, Utah 84112, United States
  • Clinical Trial Site
    Fairfax, Virginia 22031, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2025 to primary completion in Oct 2026, 17 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Nov 2026 → Oct 2026 and completion Nov 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2025
First posted
Jun 17, 2025
StartActual
May 29, 2025
Primary completionActual
Oct 30, 2026was Nov 2026
CompletionActual
Oct 30, 2026was Nov 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 17, 2026
Primary completion
Nov 30, 2026→Oct 30, 2026 (actual)
Nov 17, 2026
Study completion
Nov 30, 2026→Oct 30, 2026 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Active, not recruiting→Completed
    Primary completion Nov 30, 2026→Oct 30, 2026 (now actual)
    Study completion Nov 30, 2026→Oct 30, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07023731
Lead sponsor
Arvinas Inc.
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
May 29, 2025
Primary completion
Oct 30, 2026
Completion
Oct 30, 2026
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion